Janet Davison Rowley 1925–2013  by Olopade, Olufunmilayo I.
Leading Edge
ObituaryJanet Davison Rowley
1925–2013
Dr. Janet Rowley was internationally
renowned for her studies of chromosome
abnormalities in human leukemia and
lymphoma. We adored her closer to
home as a University of Chicago lifer and
a treasured member of our great Hyde
Park/Kenwood community. A woman
of tremendous grace and beauty, she
distinguished herself not only for her
historic scientific discoveries but also
with her sustained efforts to support the
careers of others, including myself. As
wemark her passing, our hearts are heavy
because she will be sorely missed.
Janet Davison Rowley was born in
New York City on April 5, 1925, the only
child of Hurford and Ethel Davison, both
graduates of the University of Chicago.
The family moved to Chicago when she
was 2 years old, and Janet always fondly
remembered growing up on the south
side of Chicago. Her father taught retail
store management at the college level,
and her mother taught English in the
public high schools. In 1940, after 2 years
at a Catholic girls’ high school, Janet, age
15, won a scholarship to enroll in the
Hutchins College at the University of
Chicago, which combined the last 2 years
of high school with the first 2 years of
college. She completed a bachelor ofJanet Rowleyphilosophy degree in 1944
and was accepted into the
University’s medical school,
but the quota—three women
for a class of 65—was already
filled. ‘‘I had to wait 9 months,’’
she said in an interview. ‘‘I was
only 19 at the time, so it wasn’t
a great tragedy.’’
Janet fell madly in love with
fellow medical student Donald
Rowley, MD, and the two were
married the day after she grad-
uated from medical school
on December 18, 1948. Janet
would spend the next 20 years
raising their four sons while
working part-time, including
at a Chicago clinic for children
with Down syndrome. Donald
became a renowned professor390 Cell 156, January 30, 2014 ª2014 Elsevieof pathology at the University of Chicago,
and after his early retirement, he was
totally dedicated to supporting Janet’s
career. The two traveled the world
together, but they always found time for
the extended family in Hyde Park. They
opened up their home to generations
of students, faculty, and staff at the
University of Chicago who enjoyed holi-
day celebrations and summer parties at
the Rowleys’. Generations have formed
memories around their giant Christmas
tree, which stretched to the second floor
of their lovely home. Janet and Donald
formed a partnership for the ages—the
two of them seamlessly integrated family
life with work life and supported each
other until the very end.
Janet often spoke against the intense
pressure to have early success as a
scientist. It was not until her husband’s
sabbatical at Oxford University in 1962
that Janet’s interest in chromosomes
and cancer gained focus, and she
learned the laboratory techniques that
she would later use to change the scope
of cancer diagnosis and treatment. She
made her first major discovery at age
47, when she identified the first consis-
tent chromosome translocation in any
human cancer, namely the 8;21 translo-r Inc.cation in acute myeloid leukemia (AML).
In a landmark paper in 1973, Janet
described the identification of the 9;22
translocation (Philadelphia chromosome)
in chronic myeloid leukemia (CML).
Subsequently, she identified more than
a dozen different recurring translocations
in children and adults with leukemia and
lymphoma. These discoveries changed
the view of cancer researchers regarding
the critical importance of recurring chro-
mosome abnormalities in cancer cells
and facilitated identification of novel
oncogenes at the breakpoint junctions.
In fact, it is reasonable to say that her
early discoveries galvanized the scien-
tific community in support of the Human
Genome Project and influenced a whole
generation of cancer geneticists like
myself who came of age in the golden
era of cytogenetics.
I remember my first meeting with
Janet in 1988. In her understated way,
she advised me to learn a ‘‘skill’’ and
apply it to important scientific questions.
Janet demonstrated the importance
of collaboration to accomplish greater
scientific goals. Her skill was chromo-
some banding, but the future was
in molecular genetics—so she shared
her samples with other scientists to
advance her science. Each sample was
carefully annotated as Janet worked
with a multidisciplinary team, including
James Vardiman, a hematopathologist,
and Harvey Golomb, a medical oncolo-
gist, and numerous colleagues at theUniversity of Chicago—long
before ‘‘team science’’ be-
came fashionable.
A series of International
Workshops on Chromosomes
in Leukemia provided critical
information regarding the
phenotypes associated with
specific translocations in large
numbers of patients and
showed that recurring chro-
mosomal abnormalities were
independent predictors of
response to therapy in AML
and acute lymphoblastic
leukemia (ALL). This led to
‘‘risk-adapted’’ therapy for
adult and childhood leukemia.
She described several impor-
tant translocations and/or in-
versions, including the 15;17
translocation in acute promyelocytic
leukemia (APL-M3), the 6;9 translocation
in AML, the inversion and translocation
involving chromosome 3 [inv(3)/t(3;3)] in
AML associated with increased platelet
counts, the inversion and translocation
involving chromosome 16 [inv(16)/
t(16;16)] in acute myelomonocytic leuke-
mia with abnormal eosinophils (AMMoL-
M4EO), and the 14;18 translocation in
follicular lymphoma. Although it is now
widely accepted that genomic analysis
plays a critical role in the diagnosis, sub-
classification, and selection of therapy
for patients with cancer, Janet, sitting
behind her microscope, was ahead of
the curve.
Janet’s research had a profound
impact on patient care. Her early work
on Philadelphia chromosome in CML
culminated in the most successful
example of targeted therapy and provided
a new paradigm for using molecular
diagnosis to define therapy in oncology.
Patients with newly diagnosed CML any-
where in the world can now expect to
live the course of a normal life on therapy.
Janet epitomized the ‘‘bedside to bench’’
philosophy, as observations in the clinic
led her to questions in the laboratory.
Throughout her illustrious career, Janet
was a stubborn advocate for science.
She was a leader on campus, and many
deans and presidents at the University
of Chicago frequently heard from her as
she fought for resources to support
research. Janet provided leadership to
the field and fostered public understand-
ing of science. She served as a member
of The President’s Council on Bioethics,
where she was one of the most effectivemembers championing the need for a
strong national program supporting
responsible human embryonic stem cell
research. Her patience and wisdom
allowed the committee to survive intact
for 8 years before President Obama
signed an executive order permitting
stem cell research in 2009. With her
long-term scientific partner and friend
Felix Mitelman, she cofounded and was
coeditor of Genes, Chromosomes and
Cancer, the premier cancer cytogenetics
journal worldwide. She also served on
scientific and public boards. Through
these activities, Janet provided enormous
opportunities for her mentees and pro-
moted the careers of others.
Janet was the recipient of the National
Medal of Science (1998), the Albert
Lasker Clinical Medicine Research Prize
(1998), the Benjamin Franklin Medal from
the American Philosophical Society
(2003), the Gruber Prize in Genetics
(2009), and the Presidential Medal of
Freedom (2009). The Medal of Freedom
recognizes ‘‘an especially meritorious
contribution to the security or national
interests of the United States, world
peace, cultural, or other significant public
or private endeavors.’’
Janet was clearly one of the true pio-
neers of our time, not least in her fearless
career as a woman in science at a time
when few were admitted to medical
school. One of my fondest memories of
Janet was when she stood up to ask me
a question after my plenary presentation
at the American Society of Clinical
Oncology (ASCO) in 1991. She was not a
member of ASCO, but her presence in
the large audience gave me absoluteCell 156confidence that I was right to have chosen
to study solid tumor genetics as a way
to differentiate from her. She educated
the clinical oncology community on the
importance of our scientific discoveries,
focusing attention on the way that genetic
alterations provide clues to the process
of malignant transformation of cancer.
From that moment, Janet created a path
for me to integrate genetics into clinical
oncology care.
Janet continued to direct an active and
productive laboratory until her death. I
marveled as she rode her bike to work
every day and, when she could no longer
do so, asked for the laboratory to come
to her home. Janet was restless, ambi-
tious, and kind—her son describe her
as a ‘‘bag’’ lady who picked up leaves
around the neighborhood. She was an
avid gardener and a phenomenal athlete
who climbed mountains and swam on
Lake Michigan most summer days.
She enjoyed the opera and traveled to
exotic corners of the world. Janet was
a devoted mother and grandmother who
always took the time to handwrite her
Christmas cards long after the holidays
in January. She was a pillar in our com-
munity, a most beloved mentor, and
a scientific mother who will be terribly
missed.
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